Breye Therapeutics has a paper on its oral danegaptide treatment for patients with NPDR published in Science Translational Medicine
/ Oral treatment danegaptide represents “a potential paradigm shift” toward earlier, non-invasive treatment of Non-Proliferative Diabetic Retinopathy (NPDR), say authors Study “provides compelling ...
